Please assess the completion status of the following clinical trial:

Trial Title: Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of bariatric or upper-gastrointestinal surgery (RYGB, VSG, gastrectomy, esophagectomy, or Nissen fundoplication) at least 12 months prior to the start of Screening~* History of recurrent hypoglycemia occurring after bariatric or upper-GI surgery, as documented in the medical record.~* Body mass index (BMI) of up to 40 kg/m2~* If female, must not be breastfeeding and must have a negative urine pregnancy test result~Exclusion Criteria:~* Major surgery within 6 months before randomization.~* History of or current hyperinsulinism other than Acquired Hyperinsulinism (e.g., insulin autoimmune hypoglycemia).~* Use of agents that may interfere with glucose metabolism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Avexitide 45 mg twice daily then avexitide 90 mg once daily (Type: EXPERIMENTAL): Patients will receive one of the two dosing regimens of avexitide for 14 days followed by the other dosing regimen of avextide for 14 days
- Avexitide 45 mg once daily then avexitide 90 mg twice daily (Type: EXPERIMENTAL): Patients will receive one of the two dosing regimens of avexitide for 14 days followed by the other dosing regimen of avextide for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).